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To the Editor,
We read with great interest the article entitled “An
evaluation of the effects of caﬀeic acid phenethyl ester
and Ankaferd blood stopper on secondary wound healing
of oral mucosal tissue”, published recently in the Journal
[1]. The authors indicated that Ankaferd Hemostat
(Ankaferd Blood Stopper, ABS) and caffeic acid phenethyl
ester had positive eﬀects on the oral wound healing
process. Since ABS has already been used in dental
surgery for years, it is known as not irritable to the oral
mucosa [2]. ABS antibacterial, antiinfective, and cellular
features are also established [3]. More importantly, ABS
is clinically effective in the prophylaxis and treatment
of oral mucositis secondary to chemotherapy and/or
radiotherapy in childhood cancers [4] and its safety and
efficacy in adult chemotherapy-induced oral mucositis
were also reported [5]. From the pharmacological point
of view, ABS includes the dried leaf extract (7.0 g/100
mL) of the plant Glycyrrhiza glabra [6]. The critical
molecular component of Glycyrrhiza glabra, glycyrrhizin,
has prominent antiinflammatory and antiviral effects [7].
The successful usage of glycyrrhizin in anticancer therapy
based on its inhibitory action on the high mobility group
box 1 (HMGB1) protein has previously been reported [8].
Moreover, glycyrrhizin is active for the management of
SARS-associated virus via inhibiting the replication of the
virus [9]. Glycyrrhizin action on SARS virus family could
be ascribed to the established pathogenic role of HMGB1
in the SARS disease [10]. Glycyrrhizic acid, present inside
Glycyrrhiza glabra, also has antiinflammatory effects via
inhibiting HMGB1 phosphorylation and secretion [11].
The currently ongoing outbreak of COVID-19, caused
by the SARS-CoV-2 coronavirus, enforced worldwide
researchers to drug repurposing strategies for identifying
new uses of the clinically approved or investigational
drugs that are outside the scope of the original medical
indication. Some synthetic drugs are already in the
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progress of repurposing against COVID-19. Glycyrrhiza
glabra has long been employed against coughs and colds
in Chinese Medicine and Wuhan University has proposed
a combination of diammonium glycyrrhizinate and
vitamin C for COVID-19 therapy [12]. Although herbal
medicinal products might be effective against COVID-19,
it is hard to suggest them for drug repurposing since
most of the plants are not standardized products and not
approved by any disease indication. However, ABS is an
already approved and standardized plant-based medicinal
product for the management of dental, dermal, external
and internal bleedings. Its nontoxic and nonirritable
features make it possible to be safely applied as topical
oral solution [4]. ABS inhibited the growth of nosocomial
bacterial pathogens in 72.4% to 100% of the bacteria tested,
depending on the type of the isolate [3]. Furthermore, the
in vitro yet unpublished results presented that ABS was
found to be virucidal on bovine herpes virus type 1 (BHV1) virus.
Within the light of the recent published paper in
Turkish Journal of Medical Sciences [1] regarding the
wound healing properties of ABS on oral mucosa and
the already published results about the antiinfective
effect of ABS, we propose that small-volume ampoule
solution of the ABS diluted with water shall be used as
a gargling solution for the virus-induced oropharyngeal
mucositis, clinically representing itself as ‘sore throat’.
The antimicrobial, antiinfective, virucidal, antiseptic and
wound healing features of ABS [3] could be beneficial for
the clinical management of initial steps of COVID-19
infection for instance at the oropharyngeal level.
Repurposing of the topical oral usage of ABS against
COVID-19 may be tested in clinical trials in near future
for this aim of repositioning.
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